Advances in research of rh-endostatin in the treatment of cancer
10.3760/cma.j.issn.1673-422X.2016.05.010
- VernacularTitle:重组人血管内皮抑制素治疗恶性肿瘤的研究进展
- Author:
Wenyao XIE
;
Da JIANG
;
Zhiyong YANG
;
Qian DONG
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Drug therapy;
Recombinant human endostatin
- From:
Journal of International Oncology
2016;43(5):360-363
- CountryChina
- Language:Chinese
-
Abstract:
Recombinant human endostatin (Endostar) is a broad spectrum molecular targeted drug on anti-angiogenesis that the main evidence-based data is combined chemotherapy treatment of advanced non-small cell lung cancer (NSCLC).In recent years,the researches of recombinant human endostatin used in the treatment of various malignant tumors are on the increase and achieve good effect.In addition,the researches about combined treatment methods,routes of administration,methods of medication are carried out gradually,which will be conducive to the reasonable application in clinical.
